Description

DAYVIGO 5 MG

Indications

DAYVIGO (lemborexant) is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It is intended for use in patients who have not achieved satisfactory sleep quality or duration through non-pharmacological interventions alone. DAYVIGO is prescribed as part of a comprehensive treatment plan that may include lifestyle changes and behavioral therapy.

Mechanism of Action

DAYVIGO is a dual orexin receptor antagonist (DORA) that works by inhibiting the action of orexin neuropeptides, which play a crucial role in regulating the sleep-wake cycle. Orexin A and orexin B are produced in the hypothalamus and are involved in promoting wakefulness. By blocking the receptors for these neuropeptides, DAYVIGO facilitates the onset of sleep and helps maintain sleep throughout the night, thereby addressing the symptoms of insomnia.

Pharmacological Properties

DAYVIGO is rapidly absorbed after oral administration, with peak plasma concentrations typically occurring within 1 to 3 hours. The drug has a half-life of approximately 17 hours, allowing for effective management of sleep disturbances. DAYVIGO is primarily metabolized by the liver through cytochrome P450 enzymes, particularly CYP3A4. Its pharmacokinetics can be influenced by factors such as age, sex, and liver function, necessitating careful consideration during prescribing.

Contraindications

DAYVIGO is contraindicated in patients with a known hypersensitivity to lemborexant or any of its components. It should not be used in conjunction with strong CYP3A4 inhibitors, as this may increase the risk of adverse effects and alter the drug’s efficacy. Additionally, DAYVIGO is not recommended for individuals with severe hepatic impairment, as this may lead to increased systemic exposure and potential toxicity.

Side Effects

Common side effects associated with DAYVIGO include somnolence, headache, dizziness, and fatigue. These effects are generally mild to moderate in intensity and tend to diminish over time as the body adjusts to the medication. Serious side effects, although rare, may include complex sleep behaviors such as sleepwalking, sleep driving, and other activities while not fully awake. Patients should be advised to avoid activities that require full alertness, such as driving or operating heavy machinery, until they understand how DAYVIGO affects them.

Dosage and Administration

The recommended starting dose of DAYVIGO is 5 mg taken orally once per night, approximately 30 minutes before bedtime. Depending on the individual response and tolerability, the dose may be increased to a maximum of 10 mg. It is important to take DAYVIGO on an empty stomach, as food can affect the absorption and effectiveness of the medication. Patients should be advised to adhere to the prescribed dosage and not to exceed the maximum recommended dose without consulting their healthcare provider.

Interactions

DAYVIGO may interact with other medications, particularly those that are metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can lead to increased exposure to lemborexant, heightening the risk of side effects. Conversely, strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease the effectiveness of DAYVIGO. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions

Before starting DAYVIGO, healthcare providers should assess patients for a history of sleep disorders, substance use disorders, and other psychiatric conditions. Caution is advised in patients with a history of complex sleep behaviors, as the use of DAYVIGO may exacerbate these issues. Additionally, elderly patients may be more sensitive to the effects of lemborexant; therefore, a lower starting dose may be appropriate. It is essential to monitor patients for any signs of unusual behavior or adverse reactions during treatment.

Clinical Studies

Clinical studies have demonstrated the efficacy of DAYVIGO in improving sleep onset and maintenance in patients with insomnia. In randomized, placebo-controlled trials, patients taking DAYVIGO reported significant improvements in sleep quality and duration compared to those receiving placebo. The studies indicated that DAYVIGO effectively reduced the time taken to fall asleep and increased total sleep time, with benefits observed within the first week of treatment. Long-term studies have also shown that DAYVIGO maintains its efficacy without significant tolerance development over extended use.

Conclusion

DAYVIGO 5 mg is a valuable treatment option for adults suffering from insomnia. Its unique mechanism of action as a dual orexin receptor antagonist allows for effective management of sleep disturbances, providing patients with improved sleep quality and duration. While generally well-tolerated, it is essential for patients to be aware of potential side effects and interactions with other medications. As with any medication, DAYVIGO should be used responsibly and as part of a comprehensive treatment approach, including lifestyle modifications and behavioral therapies.